denosumab biosimilar / NeuClone, Serum Institute of India - LARVOL DELTA

[VIRTUAL] NeuClone (BIO 2020) - "NeuClone's pipeline consists of 20 biosimilars, six of which have been disclosed referencing Stelara (ustekinumab), Herceptin (trastuzumab), Perjeta (pertuzumab), Synagis (palivizumab), Prolia (denosumab) and Humira (adalimumab)...Additional biosimilars referencing Perjeta, Prolia, Synagis and more are undergoing manufacturing scale-up ahead of initiating clinical trials. NeuClone is exploring potential partnerships for biosimilar mAbs through clinical development and commercialisation into North America, Europe and other selected developed world and emerging markets."

Oncology